Glancy Binkow & Goldberg Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit on Behalf of Investors ...

Glancy Binkow & Goldberg LLP reminds investors that all purchasers of the Contingent Value Rights (“CVRs”) of Sanofi (NASDAQ:GCVRZ) between March 6, 2012 and November 7, 2013, inclusive (the “Class Period”), have until February 10, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Sanofi is a global healthcare company engaged in the research, development, manufacture and marketing of healthcare products, including pharmaceuticals and vaccines. Sanofi’s multiple sclerosis therapy Lemtrada™ (alemtuzumab) has completed two Phase III clinical studies and is under review for U.S. Food and Drug Administration marketing approval in the U.S. and Europe. The Complaint filed in the United States District Court for the Southern District of New York alleges that the Company and certain of its executive officers knew or recklessly disregarded but failed to disclose that:

• Defendants’ public statements had materially misrepresented the safety and efficacy of Lemtrada and its prospects for FDA approval.
• The design of the Lemtrada trials tainted the results and lowered the likelihood of FDA approval.
• The Company lacked adequate internal controls.

To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at [phone], or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at [phone], by e-mail to [e-mail], or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLP, Los Angeles, CAMichael Goldberg, 888-773-9224orGlancy Binkow & Goldberg LLP, New York, NYGregory Linkh, [e-mail]